Protegrin-1 increases bacterial clearance in sepsis but decreases survival

Critical Care Medicine

Volumn 31, Issue 1, 2003, Pages 221-226

  Steinstraesser, Lars ^a,b   Burghard, Olaf ^b   Nemzek, Jean ^a   Fan, Ming Hui ^a   Merry, Andrew ^a   Remick, Daniel I ^a   Su, Grace L ^a   Steinau, Hans Ulrich ^b   Wang, Stewart C ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antimicrobial peptide; Cecal ligation puncture; Chemokine; Cytokine; Innate immunity; Mortality

Indexed keywords

IMIPENEM; PROTEGRIN; PROTEGRIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; CECUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; IMMUNE RESPONSE; INFLAMMATION; MORTALITY; MOUSE STRAIN; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SEPSIS; SURVIVAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLONY COUNT, MICROBIAL; CYTOKINES; MICE; MICE, INBRED BALB C; PROTEINS; SEPSIS; SURVIVAL ANALYSIS;

EID: 0037253328     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301000-00034     Document Type: Article

References (44)

1. Cryer HG: Therapeutic approaches for clinical ischemia and reperfusion injury. Shock 1997; 8:26-32
2. Wenzel RP: Anti-endotoxin monoclonal antibodies: A second look. N Engl J Med 1992; 326:1151-1153
3. Levy SB: Antibiotic resistance: An ecological imbalance. Ciba Found Symp 1997; 207:1-9
4. McKinnon PS, Tam VH: New antibiotics for infections caused by resistant organisms. Support Care Cancer 2001; 9:8-10
5. Levison ME, Mallela S: Increasing antimicrobial resistance: Therapeutic implications for enterococcal infections. Curr Infect Dis Rep 2000; 2:417-423
6. Krcmery VF, Matejicka E, Pichnova L, et al: Documented fungal infections after prophylaxis or therapy with wide spectrum antibiotics: Relationship between certain fungal pathogens and particular antimicrobials? J Chemother 1999; 11:385-390
7. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
8. Carmeli Y, Troillet N, Karchmer AW, et al: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-1132
9. Kokryakov VN, Harwig SS, Panyutich EA, et al: Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett 1993; 327:231-236
10. Zhao C, Liu L, Lehrer RI: Identification of a new member of the protegrin family by cDNA cloning. FEBS Lett 1994; 346:285-288
11. Zhao C, Ganz T, Lehrer RI: The structure of porcine protegrin genes. FEBS Lett 1995; 368:197-202
12. Aumelas A, Mangoni M, Roumestand C, et al: Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 1996; 237:575-583
13. Heller WT, Waring AJ, Lehrer RI, et al: Multiple states of beta-sheet peptide protegrin in lipid bilayers. Biochemistry 1998; 37:17331-17338
14. Mangoni ME, Aumelas A, Charnet P, et al: Change in membrane permeability induced by protegrin 1: Implication of disulphide bridges for pore formation. FEBS Lett 1996; 383:93-98
15. Harwig SS, Waring A, Yang HJ, et al: Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur J Biochem 1996; 240:352-357
16. Bellm L, Lehrer RI, Ganz T: Protegrins: New antibiotics of mammalian origin. Expert Opin Investig Drugs 2000; 9:1731-1742
17. Fortney K, Totten PA, Lehrer RI, et al: Haemophilus ducreyi is susceptible to protegrin. Antimicrob Agents Chemother 1998; 42:2690-2693
18. Steinstraesser L, Klein RD, Aminlari A, et al: Protegrin-1 enhances bacterial killing in thermally injured skin. Crit Care Med 2001; 29:1431-1437
19. Steinberg DA, Hurst MA, Fujii CA, et al: Protegrin-1: A broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother 1997; 41:1738-1742
20. Cho Y, Turner JS, Dinh NN, et al: Activity of protegrins against yeast-phase Candida albicans. Infect Immun 1998; 66:2486-2493
21. Tracey KJ, Lowry SF, Fahey TJ, et al: Anticachectin TNF monoclonal antibodies prevent septic shock during lethal endotoxemia. Nature 1987; 330:662-664
22. Arend WP, Welgus HG, Thompson RC, et al: Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85:1694-1697
23. Bone RC, Balk RA, Fein TM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23:994-1006
24. Abraham E, Anzueto A, Gutierrez G, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351:929-933
25. Eskandari MK, Bolgos G, Miller C, et al: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-2730
26. Solomkin JS, Dellinger EP, Christou NV, et al: Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212:581-591
27. Gonzenbach HR, Simmen HP, Amgwerd R: Imipenem (N-F-thienamycin) versus netilmicin plus clindamycin: A controlled and randomized comparison in intra-abdominal infections. Ann Surg 1987; 205:271-275
28. Newcomb D, Bolgos G, Green L, et al: Antibiotic treatment influences outcome in murine sepsis: Mediators of increased morbidity. Shock 1998; 10:110-117
29. Ebong S, Call D, Nemzek J, et al: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 1999; 67:6603-6610
30. DeForge LE, Remick DG: Sandwich ELISA for detection of picogram quantities of interleukin-8. Immunol Invest 1991; 20:89-97
31. Remick D, Strieter R, Eskandari M, et al: Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am J Pathol 1990; 136:49-60
32. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234:470-474
33. Alexander HR, Doherty GM, Buresh CM, et al: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173:1029-1032
34. Fahrner RL, Dieckmann T, Harwig SS, et al: Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. Chem Biol 1996; 3:543-550
35. Shafer WM, Qu X, Waring AJ, et al: Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998; 95:1829-1833
36. Steinstraesser L, Alarcon W, Fan MH, et al: Thermal injury induces expression of CD14 in human skin. Burns 2002; 28:223-230
37. Remick DG, Newcomb DE, Bolgos GL, et al: Comparison of the mortality and inflammatory response of two models of sepsis: Lipopolysaccharide versus cecal ligation and puncture. Shock 2000; 13:110-116
38. Klein RD, Su GL, Aminlari A, et al: Skin lipopolysaccharide-binding protein and IL-1beta production after thermal injury. J Burn Care Rehabil 2000; 21:345-352
39. Steinstraesser L, Tack BF, Waring A, et al: Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46:1837-1844
40. Mozes T, Ben-Efraim S, Tak CJ, et al: Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett 1991; 27:157-162
41. Patel RT, Deen KI, Youngs D, et al: Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 1994; 81:1306-1308
42. Riche FC, Cholley BP, Panis YH, et al: Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 2000; 28:433-437
43. Damas P, Canivet JL, de Groote D, et al: Sepsis and serum cytokine concentrations. Crit Care Med 1997; 25:405-412
44. Carvalho GL, Wakabayashi G, Shimazu M, et al: Anti-interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits. Surgery 1997; 122:60-68